International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.
What happened
FDA found this by reviewing records the company submitted after a March 17, 2023 request; no inspection dates are listed. FDA found the company did not test each shipment of each lot of high-risk components for identity, including United States Pharmacopeia (USP) limit tests for hazardous impurities, and that its quality unit did not adequately approve or reject components.
What FDA found
The company did not perform at least one identity test on each incoming component lot, including high-risk components that needed USP limit tests for hazardous impurities.
21 CFR 211.84(d)(1)The company's quality unit did not adequately exercise its responsibility to approve or reject components and other materials.
21 CFR 211.22(a)
What FDA wants
FDA tells the company to respond in writing within 30 working days with what it has done to fix the violations and prevent recurrence. FDA also asks for a commitment and test results for high-risk components no later than 30 calendar days, and if corrective actions cannot be completed within 15 working days, the company must explain the delay and give a schedule.
Who should pay attention
- US importers and distributors of OTC drug products
- brands that buy finished OTC drugs from this contract manufacturer
- companies relying on supplier certificates of analysis for component identity
This is a summary. Read the original letter on fda.gov.